<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38325">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01679522</url>
  </required_header>
  <id_info>
    <org_study_id>LESS-E</org_study_id>
    <nct_id>NCT01679522</nct_id>
  </id_info>
  <brief_title>Feasibility Study of Laparoendoscopic Single Site Surgical Staging for Endometrial Cancer</brief_title>
  <acronym>LESS-E</acronym>
  <official_title>Prospective Randomized Comparison of Single-port and Four-port Laparoscopic Staging Operation for Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <authority>Korea: Asan Medical Center Institutional Review Borad</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the feasibility, safety, and efficacy between single-port and four-port
      laparoscopic surgical staging in patients with early stage endometrial cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>operating time</measure>
    <time_frame>1 day (Immediately after operation)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of lymph nodes retrieved</measure>
    <time_frame>1 week after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>within 1 week after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative analgesics requirement</measure>
    <time_frame>within 1 week after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>within 6 months aftr surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>surgical stress response</measure>
    <time_frame>within 2 days after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transfusion requirement and amount</measure>
    <time_frame>within 1 week after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative complication</measure>
    <time_frame>within 1 month after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time interval to return to work</measure>
    <time_frame>within 2 months after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrence free survival</measure>
    <time_frame>2 year after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Single-port surgery group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-port laparoscopic surgical staging including total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Four-port surgery group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Four-port laparoscopic surgical staging including total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>single-port laparoscopic surgical staging</intervention_name>
    <description>single-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection</description>
    <arm_group_label>Single-port surgery group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Four-port laparoscopic surgical staging</intervention_name>
    <description>Four-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection</description>
    <arm_group_label>Four-port surgery group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated, histologically confirmed endometrial cancer

          -  Presumed FIGO stage 1

          -  Endometrioid adenocarcinoma

          -  patient who is planned to undergo surgical staging

          -  adequate oran function

               1. WBC &gt; 3000 cells/mcl

               2. Platelets &gt; 100000/mcl

               3. Creatinine &lt; 2.0 mg/dL

               4. Bilirubin &lt; 1.5 * normal and SGOT or SGPT &lt; 3 * normal

          -  American Society of Anesthesiologists Physical Status I-II

          -  Eastern Cooperative Oncology Group performance status 0-2

          -  Patients who have signed an approved Informed Consent

        Exclusion Criteria:

          -  Uncontrolled medical disease

          -  Active infectious disease requiring antibiotics

          -  Previous pelvic radiation therapy

          -  Pregnant and lactating woman

          -  Patient who requires additional surgical procedures which are not necessary for
             surgical staging of endometrial cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joo-Hyun Nam, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joo-Hyun Nam, M.D., Ph.D.</last_name>
    <phone>82-10-3010-3633</phone>
    <email>jhnam@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo-Hyun Nam, M.D., Ph.D.</last_name>
      <phone>82-2-3010-3633</phone>
      <email>jhnam@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Jong-Hyeok Kim, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dae-Yeon Kim, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeong-Yeol Park, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joo-Hyun Nam, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 8, 2012</lastchanged_date>
  <firstreceived_date>September 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Joo-Hyun Nam</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>endometrial cancer</keyword>
  <keyword>laparoscopic surgical staging</keyword>
  <keyword>single-port</keyword>
  <keyword>four-port</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Sarcoma, Endometrial Stromal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
